Table I.
Alteration of Kidins220 in tumourigenesis and the related signalling pathway.
| Tumour type | Alteration | Effect | Signalling pathways | (Refs.) |
|---|---|---|---|---|
| Cutaneous melanoma | Increased expression | Melanoma formation, migration and invasion | MEK/ERK signalling pathway | (31,32) |
| Neuroblastoma | Increased expression | Proliferation | p21/cyclin D1 | (35) |
| NGF-regulated signalling | (33) | |||
| Transition from N-type to S-type | (34) | |||
| Castration-resistant prostate cancer (CRPC) | Increased expression | Angiogenesis | VEGF/VEGFR and PI13K/AKT signalling pathways | (36) |
| Ph-like acute lymphoblastic leukemia (ALL) | Gene fusion with PAX5 | Proliferation and survival | ERK signalling pathway | (44) |
| Pediatric high-grade glioma | Intragenic copy number breakpoint | n.d. | n.d. | (45) |
Kidins220, kinase D-interacting substrate of 220 kDa; VEGFR, vascular endothelial growth factor receptors; NGF, nerve growth factor; n.d., not determined.